scispace - formally typeset
P

Paul J. Perry

Researcher at Touro University California

Publications -  182
Citations -  9133

Paul J. Perry is an academic researcher from Touro University California. The author has contributed to research in topics: Olanzapine & Atypical antipsychotic. The author has an hindex of 51, co-authored 182 publications receiving 8664 citations. Previous affiliations of Paul J. Perry include University of Iowa Hospitals and Clinics & Roy J. and Lucille A. Carver College of Medicine.

Papers
More filters
Journal ArticleDOI

Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response.

TL;DR: An analysis of the literature on tricyclic antidepressant level in blood using receiver operating characteristics curves as the primary statistical tool was performed and a significant curvilinear relationship between therapeutic response and nortriptyline was observed.
Journal ArticleDOI

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.

TL;DR: A receiver operating characteristic (ROC) curve analysis of 12-hour olanzapine concentrations and treatment response from the North American Double-Blind Olanzapine Trial found a 12- hour olanZapine plasma concentration of >23.2 ng/mL was a predictor of therapeutic response in acutely ill patients with schizophrenia.
Journal ArticleDOI

Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.

TL;DR: Bupropion and placebo recipients did equally well in a short-term trial, with improvement seen as early as the first week of treatment.
Journal ArticleDOI

Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men

TL;DR: Despite significant elevations in serum total and free testosterone, healthy young men do not demonstrate increased serum or semen PSA levels, or increased prostate volume in response to exogenous testosterone injections.
Journal ArticleDOI

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.

TL;DR: Use of olanzapine plasma concentrations of > 9 ng/mL as a predictor for treatment response in acutely ill schizophrenic patients is practicable because this therapeutic marker significantly increases the likelihood of a patient responding to olanZapine.